Arzneimittelforschung 2006; 56(3): 239-248
DOI: 10.1055/s-0031-1296716
Antibiotics · Antiviral Drugs · Chemotherapeutics · Cytostatics
Editio Cantor Verlag Aulendorf (Germany)

Synthesis and Evaluation of Antimicrobial and Anticonvulsant Activities of Some New 3-[2-(5-Aryl-1,3,4-oxadiazol-2-yl/4-Carbethoxymethylthiazol-2-yl)imino-4-thiazolidinon-5-ylidene]-5-substituted/nonsubstituted 1H-indole-2-ones and Investigation of Their Structure-Activity Relationships

Handan Altintaş
1   Department of Pharmaceutical Chemistry, Faculty of Pharmacy, Istanbul University, Istanbul, Turkey
,
Öznur Ates
1   Department of Pharmaceutical Chemistry, Faculty of Pharmacy, Istanbul University, Istanbul, Turkey
,
B. Sönmez Uydeş-Doğan
2   Department of Pharmacology, Faculty of Pharmacy, Istanbul University, Istanbul, Turkey
,
F. Alp İlkay
2   Department of Pharmacology, Faculty of Pharmacy, Istanbul University, Istanbul, Turkey
,
Deniz Kaleli
2   Department of Pharmacology, Faculty of Pharmacy, Istanbul University, Istanbul, Turkey
,
Osman Özdemir
2   Department of Pharmacology, Faculty of Pharmacy, Istanbul University, Istanbul, Turkey
,
Seher Birteksöz
3   Department of Pharmaceutical Microbiology, Faculty of Pharmacy, Istanbul University, Istanbul, Turkey
,
Gülten Ötük
3   Department of Pharmaceutical Microbiology, Faculty of Pharmacy, Istanbul University, Istanbul, Turkey
,
Dilek Satana
4   Department of Microbiology, Istanbul Faculty of Medicine, Istanbul University, Istanbul, Turkey
,
Meltem Uzun
4   Department of Microbiology, Istanbul Faculty of Medicine, Istanbul University, Istanbul, Turkey
› Author Affiliations
Further Information

Publication History

Publication Date:
23 December 2011 (online)

Summary

In the present study, 20 new compounds having 3-[2-(5-aryl-1,3,4-oxadiazol-2-yl) imino-4-thiazolidinon-5-ylidene]-5-substituted/nonsubstituted 1H-indole-2-one (I–XII) and 3-[2-(4-carbethoxymethylthiazol-2-yl)imino-4-thiazolidinon-5-ylidene]-5-substituted/nonsubstituted 1H-indole-2-one (XIII-XX) systems were synthesized. The structures were confirmed by spectral methods (UV, IR, 1H-NMR, 13C-NMR, 13C-DEPT (135), electron impact mass spectrometry) and elemental analysis. All compounds were tested for in vitro antimicrobial activity against Staphylococcus aureus ATCC 6538, Staphylococcus epidermidis ATCC 12228, Escherichia coli ATCC 8739, Klebsiella pneumoniae ATCC 4352, Pseudomonas aeruginosa ATCC 1539, Salmonella typhi, Shigella flexneri, Proteus mirabilis ATCC 14153, Candida albicans ATCC 10231, Microsporum gypseum (NCPF-580), Microsporum canis, Trichophyton mentagrophytes and Trichophyton rubrum and some of them were found to be active. Especially, compound I was more active than cefuroxime sodium (CAS 56238-63-2) which was used as a standard, and the activity of compound XII was close to that of cefuroxime sodium against Staphylococcus epidermidis ATCC 12228. Primary screening for antituberculous activity was conducted at 6.25 µg/ml against Mycobacterium tuberculosis H37Rv in BACTEC 12B medium using the BACTEC 460 radiometric system. The anticonvulsant activities of selected prototoype compounds (I, IV-VI, VIII, XI, XIII, XVI-XVIII) administered at doses of 50-200 mg/kg (i.p.) were evaluated using the pentetrazol test (PTZ) in mice.

Zusammenfassung

Synthese und Evaluierung der antimikrobiellen und antikonvulsiven Wirkung von neuen 3-[2-(5-Aryl-1,3,4-oxadiazol-2-yl/4-Carbethoxymethylthiazol-2-yl)-imino-4-thiazolidinon-5-yliden]-5-substituierten/unsubstituierten 1H-Indol-2-onen sowie Untersuchung ihrer Struktur-Wirkungs-Beziehungen

In der vorliegenden Arbeit wurden 20 neue Verbindungen mit 3-[2-(5-Aryl-1,3,4-oxadiazol-2-yl)imino-4-thiazolidinon-5-yliden]-5-substituierten/unsubstituierten 1H-indol-2-onen (I–XII) und 3-[2-(4-Carbethoxymethylthiazol-2-yl)imino-4-thiazolidinon-5-yliden]-5-substituierten/unsubstituierten 1H-indol-2-onen (XIII–XX) als Grundstruktur dargestellt. Die Aufklärung der Strukturen erfolgte mit Hilfe spektroskopischer Methoden (UV, IR, 1H-NMR, 13C-NMR, 13C-DEPT (135), Massenspektroskopie) sowie mittels Elementaranalyse. Alle Verbindungen wurden in vitro gegen Staphylococcus aureus ATCC 6538, Staphylococcus epidermidis ATCC 12228, Escherichia coli ATCC 8739, Klebsiella pneumoniae ATCC 4352, Pseudomonas aeruginosa ATCC 1539, Salmonella typhi, Shigella flexneri, Proteus mirabilis ATCC 14153, Candida albicans ATCC 10231, Microsporum gypseum (NCPF-580), Microsporum canis, Trichophyton mentagrophytes und Trichophyton rubrum getestet. Gegen Staphylococcus epidermidis ATCC 12228 erwies sich die Verbindung I als aktiver als die Standardsubstanz Cefuroxim-Natrium (CAS 56238-63-2); die Substanz XII war gegen denselben Stamm gleich wirksam wie Cefuroxim-Natrium. Alle Substanzen wurden auβerdem in vitro gegen Mycobacterium tuberculosis H37Rv auf antituberkulöse Wirkung geprüft, wobei als Testmetode das radiometrische System BACTEC 460 und BACTEC 12B Medium zur Anwendung kamen. Die antikonvulsive Wirkung von Prototypen (I, IV–VI, VIII, XI, XIII, XVI–XVIII) wurde im Pentetrazol-Test an Mäusen untersucht.